0000000000022726

AUTHOR

Sebastian Göbel

showing 19 related works from this author

Telemedicine-Based Specialized Care Improves the Outcome of Anticoagulated Individuals with Venous Thromboembolism-Results from the thrombEVAL Study.

2020

Venous thromboembolism (VTE) is a life-threatening disease with risk of recurrence. Oral anticoagulation (OAC) with vitamin K antagonists (VKA) is effective to prevent thromboembolic recurrence. We aimed to investigate the quality of OAC of VTE patients in regular medical care (RMC) compared to a telemedicine-based coagulation service (CS). The thrombEVAL study (NCT01809015) is a prospective, multi-center study to investigate OAC treatment (recruitment: January 2011&ndash

medicine.medical_specialtyANTITHROMBOTIC THERAPYPULMONARY-EMBOLISMvenous thromboembolismlcsh:Medicine030204 cardiovascular system & hematologyRate ratioWARFARINArticle03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicinemedicineORAL ANTICOAGULATION030212 general & internal medicineAdverse effectcoagulation serviceINR CONTROLNORMALIZED RATIO CONTROLPRACTICAL MANAGEMENTbusiness.industrySTROKE PREVENTIONlcsh:RHazard ratioWarfarinAtrial fibrillationGeneral Medicinemedicine.diseaseConfidence intervalMEDICAL-CAREPulmonary embolismvitamin K antagonistsATRIAL-FIBRILLATIONe-healthbusinessoral anticoagulation therapymedicine.drugJournal of clinical medicine
researchProduct

Monitoring White Blood Cell Mitochondrial Aldehyde Dehydrogenase Activity: Implications for Nitrate Therapy in Humans

2009

Recent animal data suggest that reduced lipoic acid (LA) prevents oxidative inhibition of the nitrate bioactivating enzyme, the mitochondrial aldehyde dehydrogenase (ALDH-2), and that pentaerythritol tetranitrate (PETN) does not induce nitrate tolerance because of its intrinsic antioxidative properties, thereby preserving ALDH-2 activity. We sought to determine whether ALDH-2 activity in circulating white blood cells (WBCs) can be used to monitor nitrate tolerance and whether LA can prevent nitroglycerin tachyphylaxis in humans. Eight healthy male volunteers received, in randomized order, a single dose of glyceryl trinitrate (GTN; 0.8 mg), PETN (80 mg), or GTN plus LA (600 mg) orally. GTN (…

MaleMyocardial IschemiaAldehyde dehydrogenasePentaerythritol tetranitrateVasodilationTachyphylaxisPharmacologymedicine.disease_causeMitochondria Heartchemistry.chemical_compoundAnimal dataWhite blood cellLeukocytesmedicineAnimalsHumansRats WistarPharmacologyNitratesbiologyAldehyde DehydrogenaseRatsEnzyme ActivationVasodilationLipoic acidmedicine.anatomical_structurechemistrybiology.proteinMolecular MedicineOxidative stresscirculatory and respiratory physiologyJournal of Pharmacology and Experimental Therapeutics
researchProduct

Management of Oral Anti-Coagulation in Patients with Heart Failure-Insights from the ThrombEVAL Study

2018

AbstractPatients with heart failure (HF) are frequently anti-coagulated with vitamin K-antagonists (VKAs). The use of long-acting VKA may be preferable for HF patients due to higher stability of plasma concentrations. However, evidence on phenprocoumon-based oral anti-coagulation (OAC) therapy in HF is scarce. The aim of this study was to assess the impact of the presence of HF on quality of phenprocoumon-based OAC and the subsequent clinical outcome. Quality of OAC therapy and the incidence of adverse events were analysed in a cohort of regular care (n = 2,011) from the multi-centre thrombEVAL study program (NCT01809015) stratified by the presence of HF. To assess the modifiability of outc…

MaleAdministration Oralheart failureclinical outcomeED AMERICAN-COLLEGE030204 cardiovascular system & hematologyTHERAPY ANTITHROMBOTIC THERAPYCohort StudiesPhenprocoumon0302 clinical medicinequality of careGermanyProspective Studies030212 general & internal medicineProspective cohort studyAged 80 and overOUTCOMESIncidenceHazard ratioHematologyTreatment OutcomeCohortFemaleCLINICAL-PRACTICE GUIDELINESSINUS RHYTHMmedicine.drugCohort studyRiskmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsHemorrhageWARFARINEJECTION FRACTION03 medical and health sciencesInternal medicinemedicineHumansAdverse effectAgedbusiness.industryWarfarinhealth care modelAnticoagulantsmedicine.diseaseoral anti-coagulationHeart failureATRIAL-FIBRILLATIONPhenprocoumonADVERSE EVENTSbusinessANTICOAGULANT-THERAPY
researchProduct

e-Health-based management of patients receiving oral anticoagulation therapy: results from the observational thrombEVAL study

2017

Essentials e-Health based health care by an expert centre may advance management of oral anticoagulation. Outcome of patients was compared between an e-health based coagulation service and regular care. Patients in the coagulation service cohort experienced a significantly better clinical outcome. Lower risk for adverse events was related to anticoagulation-specific and non-specific outcome. SummaryBackground Management of oral anticoagulation (OAC) therapy is essential to minimize adverse events in patients receiving vitamin K-antagonists (VKAs). Data on the effect of e-health-based anticoagulation management systems on the clinical outcome of OAC patients are limited. Objectives To compar…

MalePediatricsVitamin KAdministration OralComorbidity030204 cardiovascular system & hematologyRate ratioSERVICE0302 clinical medicineRisk FactorsGermanyUSUAL MEDICAL-CAREClinical endpointProspective Studies030212 general & internal medicineAged 80 and overOUTCOMESHazard ratioDABIGATRANHematologyMiddle AgedHospitalizationTreatment OutcomeCohortdelivery of healthcareFemaleepidemiologyPatient SafetytelemedicineCohort studymedicine.drugmedicine.medical_specialtyanticoagulantsHemorrhageLower riskpatient outcome assessmentWARFARIN03 medical and health sciencesThromboembolismmedicineNONVALVULAR ATRIAL-FIBRILLATIONHumansQUALITYInternational Normalized RatioAdverse effectBlood CoagulationMETAANALYSISAgedProportional Hazards ModelsRivaroxabanbusiness.industrySTROKE PREVENTIONRIVAROXABANbusinessFollow-Up Studies
researchProduct

PHQ-2 and GAD-2 scores predict mortality in patients undergoing oral anticoagulation

2015

Psychiatry and Mental healthClinical Psychologymedicine.medical_specialtybusiness.industryInternal medicinemedicineIn patientbusinessOral anticoagulationJournal of Psychosomatic Research
researchProduct

Temporal trends and predictors of inhospital death in patients hospitalised for heart failure in Germany.

2020

Abstract Aims We investigated trends in incidence, case fatality rate, patient characteristics and adverse inhospital events of patients hospitalised for heart failure in Germany. Methods and results The German nationwide inpatient sample (2005–2016) was used for this analysis. Patients hospitalised due to heart failure were selected for analysis. Temporal trends in the incidence of hospitalisations, case fatality rate and treatments were analysed and predictors of inhospital death were identified. The analysis comprised a total number of 4,539,140 hospitalisations (52.0% women, 81.0% aged ≥70 years) due to heart failure. Although hospitalisations increased from 381 (2005) to 539 per 100,00…

Heart transplantationHeart FailureMalemedicine.medical_specialtyEpidemiologybusiness.industryIncidence (epidemiology)medicine.medical_treatmentPatient characteristicsComorbiditymedicine.diseaseHospitalizationHeart failureGermanyCase fatality rateEmergency medicineMedicineHumansIn patientFemaleHospital MortalityCardiology and Cardiovascular MedicinebusinessAgedEuropean journal of preventive cardiology
researchProduct

Relevance of depression for anticoagulation management in a routine medical care setting: results from the ThrombEVAL study program

2014

Summary Background Depressive symptoms have detrimental effects on quality of life and mortality. Poor adherence to a treatment regimen is a potential mechanism for the increased risk of adverse medical events associated with depression. Regarding oral anticoagulation with vitamin K antagonists, adherence is crucial for the outcome. Little is known about the clinical relevance of current depressiveness for anticoagulation treatment. Objectives To examine the impact of current depressiveness on anticoagulation treatment in regular medical care. Patients/Methods We examined the association between clinically significant depressiveness as assessed by the Patient Health Questionnaire-2 ≥ 2 (PHQ…

Malemedicine.medical_specialtyCross-sectional studyAdministration OralHealth literacyMedication AdherenceCohort StudiesPatient satisfactionQuality of lifeAmbulatory careSurveys and QuestionnairesInternal medicineAmbulatory CarePrevalenceHumansMedicineClinical significanceInternational Normalized RatioDepression (differential diagnoses)AgedDepressionbusiness.industryAnticoagulantsHematologyMiddle AgedCross-Sectional StudiesTreatment OutcomePatient SatisfactionMultivariate AnalysisPhenprocoumonQuality of LifePhysical therapyFemalebusinessCohort studyJournal of Thrombosis and Haemostasis
researchProduct

Subtherapeutic Anticoagulation Control under Treatment with Vitamin K-Antagonists—Data from a Specialized Coagulation Service

2019

AbstractIn contrast to overanticoagulation, evidence on risk factors and outcome of subtherapeutic oral anticoagulation (OAC) with vitamin K-antagonists (VKAs) under optimum care is limited. We investigated the clinical phenotype, anticoagulation control, and clinical outcome of 760 VKA patients who received OAC therapy by a specialized coagulation service in the thrombEVAL study (NCT01809015). During 281,934 treatment days, 278 patients experience ≥ 1 episode of subtherapeutic anticoagulation control and had lower quality of OAC therapy compared to 482 patients without subtherapeutic international normalized ratio: 67.6%, interquartile range (IQR) 54.9%/76.8% versus 81.0%, IQR 68.5%/90.4%;…

MaleQuality Control0301 basic medicineVitaminmedicine.medical_specialtyVitamin KAdministration OralComorbidity030204 cardiovascular system & hematologyVitamin k03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFibrinolytic AgentsRecurrenceRisk FactorsInterquartile rangeInternal medicineAtrial FibrillationmedicineHumansThrombolytic TherapyInternational Normalized RatioBlood CoagulationStrokeAgedProportional Hazards ModelsAged 80 and overbusiness.industryProportional hazards modelCase-control studyAnticoagulantsHematologyMiddle Agedmedicine.diseaseComorbidityPhenotypeTreatment Outcome030104 developmental biologyCoagulationchemistryCase-Control StudiesFemalebusinessFollow-Up StudiesThrombosis and Haemostasis
researchProduct

Sirolimus-Induced Vascular Dysfunction

2008

Objectives This study sought to analyze mechanisms that mediate vascular dysfunction induced by sirolimus. Background Despite excellent antirestenotic capacity, sirolimus-eluting stents have been found to trigger coronary endothelial dysfunction and impaired re-endothelialization. Methods To mimic the continuous sirolimus exposure of a stented vessel, Wistar rats underwent drug infusion with an osmotic pump for 7 days. Results Sirolimus treatment caused a marked degree of endothelial dysfunction as well as a desensitization of the vasculature to the endothelium-independent vasodilator nitroglycerin. Also, sirolimus stimulated intense transmural superoxide formation as detected by dihydroeth…

medicine.medical_specialtyEndotheliumVasodilationNitric oxidechemistry.chemical_compoundInternal medicinemedicinecardiovascular diseasesEndothelial dysfunctionNADPH oxidaseNicotinamidebiologybusiness.industrySuperoxideequipment and suppliesmedicine.diseasesurgical procedures operativemedicine.anatomical_structureEndocrinologychemistrySirolimuscardiovascular systembiology.proteinCardiology and Cardiovascular Medicinebusinessmedicine.drugJournal of the American College of Cardiology
researchProduct

History of deep vein thrombosis is a discriminator for concomitant atrial fibrillation in pulmonary embolism.

2015

Pulmonary embolism (PE) is the consequence of deep vein thrombosis (DVT) in 70% of all cases. Although, PE and DVT are commonly related to risk factors of Virchow's triad, both entities are linked to cardiovascular risk factors, but risk factors seem differently important in both entities.We aimed to investigate clinical profile and outcome of patients with PE history stratified by concomitant DVT.Data from the observational multi-center thrombEVAL-study were analyzed.The sample (N=2,318) comprised 295 PE patients, of whom 69.2% (N=204) had DVT. Individuals without DVT were older and had higher prevalence of concomitant atrial fibrillation (AF), chronic lung diseases, coronary artery diseas…

Malemedicine.medical_specialtyDeep veinCoronary artery diseaseRisk FactorsInternal medicineAtrial FibrillationmedicineHumanscardiovascular diseasesAgedAged 80 and overVenous Thrombosisbusiness.industryAtrial fibrillationHematologyOdds ratiomedicine.diseaseThrombosisPulmonary embolismVenous thrombosismedicine.anatomical_structureHeart failureCardiologyFemalebusinessPulmonary EmbolismThrombosis research
researchProduct

Relevance of Polypharmacy for Clinical Outcome in Patients Receiving Vitamin K Antagonists.

2018

BACKGROUND Although polypharmacy is associated with a negative clinical outcome in various settings and commonly observed in patients receiving oral anticoagulation therapy, evidence on the relevance for the clinical outcome of anticoagulated patients is currently limited. The aim of the study was to investigate the effect of polypharmacy on the clinical outcomes among patients taking phenprocoumon. DESIGN Prospective cohort study. SETTING Regular medical care. PARTICIPANTS Information on 2011 individuals receiving vitamin K antagonists was available for analysis from the prospective multicenter thrombEVAL study. MEASUREMENTS Data were obtained from clinical visits, computer-assisted interv…

Malemedicine.medical_specialtyVitamin KAdministration OralHemorrhage030204 cardiovascular system & hematologyPhenprocoumonCohort Studies03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineGermanyPrevalenceMedicineHumansCumulative incidenceDrug Interactions030212 general & internal medicineInternational Normalized RatioMultiple Chronic ConditionsProspective StudiesRisk factorMortalityProspective cohort studyAdverse effectAgedPolypharmacybusiness.industryMedical recordHazard ratioAnticoagulantsHospitalizationPolypharmacyFemaleGeriatrics and GerontologyDrug Monitoringbusinessmedicine.drugJournal of the American Geriatrics Society
researchProduct

Symptoms of depression and anxiety predict mortality in patients undergoing oral anticoagulation: Results from the thrombEVAL study program

2015

Abstract Background/objectives Depression and anxiety are highly prevalent in cardiovascular patients. Therefore, we examined whether the 4-item Patient Health Questionnaire (PHQ-4, measuring symptoms of depression and anxiety) predicts all-cause mortality in outpatients with long-term oral anticoagulation (OAC). Methods The sample comprised n=1384 outpatients from a regular medical care setting receiving long-term OAC with vitamin K antagonists. At baseline, symptoms of anxiety and depression were assessed with the PHQ-4 and the past medical history was taken. The outcome was all-cause mortality in the 24month observation period. The median follow-up time was 13.3months. Results N=191 pati…

Malemedicine.medical_specialtyVitamin KSickness Impact ProfileSurveys and QuestionnairesInternal medicinemedicineHumansMass ScreeningMedical historyProspective StudiesScreening proceduresDepression (differential diagnoses)AgedAged 80 and overDepressive DisorderPast medical historybusiness.industryMortality rateHazard ratioAnticoagulantsMiddle AgedAnxiety DisordersPatient Health QuestionnaireCardiovascular DiseasesPhysical therapyAnxietyFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct

Sex-specific differences drive temporal trends and outcomes of patients hospitalized for heart failure in Germany

2020

Despite remarkable improvements in treatment of cardiovascular disease, heart failure (HF) is still characterized by high mortality rate. Sex-specific differences in HF have been described, but underlying reasons are widely unexplored.The nationwide German inpatient sample (2005-2016) was used for this sex-specific analyses. Temporal trends on hospitalizations, mortality, and treatments were analysed and independent predictors of adverse outcomes identified.The analysis comprises 4,538,977 hospitalizations due to HF (52.0%women) in Germany (2005-2016). Although women were older (median 82(IQR75-87) vs.76(69-82),P  0.001), coronary artery disease (CAD, 50.3% vs. 30.7%,P  0.001) was more prev…

Malemedicine.medical_specialtyTime FactorsDatabases FactualAdverse outcomesMEDLINEDisease030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciencesSex Factors0302 clinical medicineGermanyInternal medicineCase fatality ratePrevalencemedicineHumansHospital Mortality030212 general & internal medicineHealthcare DisparitiesAgedAged 80 and overHeart Failurebusiness.industryIncidenceMortality rateIncidence (epidemiology)Health Status Disparitiesmedicine.diseaseSex specificHospitalizationOutcome and Process Assessment Health CareTreatment OutcomeHeart Disease Risk FactorsHeart failureFemaleCardiology and Cardiovascular MedicinebusinessProgress in Cardiovascular Diseases
researchProduct

Rationale, design and baseline characteristics of the MyoVasc study: A prospective cohort study investigating development and progression of heart fa…

2020

Abstract Background Heart failure (HF) is a poly-aetiological syndrome with large heterogeneity regarding clinical presentation, pathophysiology, clinical outcome and response to therapy. The MyoVasc study (NCT04064450) is an epidemiological cohort study investigating the development and progression of HF. Methods The primary objective of the study is (a) to improve the understanding of the pathomechanisms of HF across the full spectrum of clinical presentation, (b) to investigate the current clinical classifications of HF, and (c) to identify and characterize homogeneous subgroups regarding disease development using a systems-oriented approach. Worsening of HF, that is, the composite of tr…

AdultMalemedicine.medical_specialtyResponse to therapyEpidemiologyCohort StudiesmedicineHumansProspective StudiesIntensive care medicineProspective cohort studyAgedBiological Specimen BanksAged 80 and overHeart Failurebusiness.industryStroke VolumeMiddle Agedmedicine.diseaseSystems medicineBaseline characteristicsHeart failureFemalePresentation (obstetrics)Cardiology and Cardiovascular MedicinebusinessEuropean journal of preventive cardiology
researchProduct

Specialized Management of Oral Anticoagulation Therapy Improves Outcome in Patients with Chronic Renal Insufficiency

2020

Oral anticoagulation (OAC) is effective at preventing and treating thromboses and thromboembolism in patients with normal renal function. We aimed to research the impact of severe renal failure (RF) on patient outcome and to determine the potential benefit of caring for these patients in a specialized coagulation service (CS). A total of 1516 usual medical care patients and 756 CS-managed patients of the thrombEVAL multicenter (21 centers), prospective, cohort study (NCT01809015) were analyzed in a 3-year follow-up. Patients with RF (serum creatinine &gt

medicine.medical_specialtymedicine.medical_treatmentlcsh:MedicineRenal function030204 cardiovascular system & hematologyArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineIn patient030212 general & internal medicineRenal replacement therapyAdverse effectcoagulation serviceOral anticoagulationoral anticoagulationCreatininevitamin k-antagonistsbusiness.industrylcsh:RHazard ratioGeneral Medicineadverse eventschemistrybusinesschronic kidney diseaseCohort studyJournal of Clinical Medicine
researchProduct

Association of Global Longitudinal Strain With Clinical Status and Mortality in Patients With Chronic Heart Failure.

2021

IMPORTANCE: Global longitudinal strain (GLS) is an emerging echocardiographic biomarker of cardiac function in heart failure (HF). Evidence from large-scale studies comprehensively investigating GLS for its association with clinical phenotypes and mortality in asymptomatic and symptomatic chronic HF is limited. OBJECTIVE: To assess the factors associated with GLS and its prognostic value in patients with chronic HF. DESIGN, SETTING, AND PARTICIPANTS: The observational, prospective MyoVasc cohort study enrolled 3289 individuals with asymptomatic to symptomatic HF between January 17, 2013, and April 27, 2018. The median follow-up was 3.2 years (interquartile range, 2.0-4.0 years). Participant…

Cardiac function curveMalemedicine.medical_specialty030204 cardiovascular system & hematologyAsymptomatic03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicinemedicineHumans030212 general & internal medicineMyocardial infarctionProspective StudiesAgedOriginal InvestigationHeart Failurebusiness.industryHazard ratioPatient AcuityAtrial fibrillationHeartMiddle Agedmedicine.diseasePrognosisEchocardiographyHeart failureFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkersCohort studyJAMA cardiology
researchProduct

Cost-effectiveness of a Telemedicine-based Coagulation Service versus Routine Medical Care for the Management of Patients Receiving Vitamin K-antagon…

2019

Service (business)Telemedicinebusiness.industryCost effectivenessMedicineCoagulation (water treatment)Medical emergencyVitamin kbusinessmedicine.diseaseMedical careScience meets clinical practice
researchProduct

The relevance of depressive symptoms for the outcome of patients receiving vitamin K antagonists: results from the thrombEVAL cohort study.

2020

Abstract Aims Although depressive symptoms are highly prevalent in patients receiving oral anticoagulation (OAC), the relevance of depression for the outcome of anticoagulated individuals is unknown. Methods and results We analysed data from the multicentre cohort study thrombEVAL (NCT01809015) investigating the efficacy of OAC with vitamin K antagonists. There was an independent study monitoring, and an independent review panel assessed the endpoints. Out of n = 1558 participants, information about depressive symptoms, as measured by the two-item screener of the patient health questionnaire (PHQ-2), was available in n = 1405 individuals. The mean follow-up period was 28.04 months, with a s…

medicine.medical_specialtyVitamin KProportional hazards modelbusiness.industryDepressionHazard ratioAnticoagulantsVitamin kConfidence intervalPatient Health QuestionnaireCohort StudiesInternal medicineThromboembolismmedicineHumansPharmacology (medical)Cardiology and Cardiovascular MedicineAdverse effectbusinessDepression (differential diagnoses)Cohort studyEuropean heart journal. Cardiovascular pharmacotherapy
researchProduct

Intake of Vitamin K Antagonists and Worsening of Cardiac and Vascular Disease: Results From the Population‐Based Gutenberg Health Study

2018

Background Preclinical data have indicated a link between use of vitamin K antagonists ( VKA ) and detrimental effects on vascular structure and function. The objective of the present study was to determine the relationship between VKA intake and different phenotypes of subclinical cardiovascular disease in the population. Methods and Results Clinical and laboratory data, as well as medical–technical examinations were assessed from 15 010 individuals aged 35 to 74 years during a highly standardized 5‐hour visit at the study center of the population‐based Gutenberg Health Study. In total, the study sample comprised 287 VKA users and 14 564 VKA nonusers. Multivariable analysis revealed an in…

Male0301 basic medicineEpidemiologyPROGRESSION030204 cardiovascular system & hematologyVitamin kCarotid Intima-Media ThicknessTHERAPYGastroenterologyAdrenomedullin0302 clinical medicineRisk Factorscardiovascular diseaseGermanyAtrial FibrillationNatriuretic Peptide BrainMatrix gla proteinOriginal ResearchVenous Thrombosisoral anticoagulationRISKbiologyMiddle AgedStrokevitamin K antagonistsC-Reactive ProteinCardiovascular DiseasesFemaleCardiology and Cardiovascular MedicineAtrial Natriuretic Factormedicine.drugAdultmedicine.medical_specialtyPopulation basedMATRIX GLA-PROTEINWARFARIN03 medical and health sciencesVascular StiffnessInternal medicineORAL ANTICOAGULANTmedicineHumansAnkle Brachial IndexVascular structureProtein PrecursorsAgedInflammationVascular diseasebusiness.industryWarfarinAnticoagulantsFibrinogenStroke Volumepharmacogenomic variantsARTERIALmedicine.diseasePreclinical dataPeptide FragmentsCALCIFICATION030104 developmental biologyAsymptomatic DiseasesPhenprocoumonbiology.proteinPulmonary EmbolismbusinessCalcificationJournal of the American Heart Association
researchProduct